Combi Flora Antipylori with Pylopass

Combi Flora Antipylori - with the bacterial strain Pylopass

Infections with the stomach bacterium Helicobacter pylori can lead to various digestive complaints and other symptoms in the digestive tract. The new Combi Flora Antipylori from effective nature is suitable in such cases, but also for preventive, effective use. The contained Pylopass™ strain Lactobacillus reuteri DSM17648 binds the pathogen and supports you in its elimination from the body.

The Pylopass™ strain of bacteria has been shown to bind the widespread Helicobacter pylori in the gastrointestinal tract and contribute to its elimination. By taking these Combi Flora capsules, after prior medical consultation, one can counteract infection with the gastric bacterium by resorting to an alternative to antibiotics. Combi Flora Antipylori from effective nature can also be taken prophylactically - in the absence of the bacterium it has no negative effects.

Helicobacter pylori - a widespread stomach bacterium

Half of humanity has an infection with the gastric bacterium H. pylori, making it the second most common bacterial infection worldwide after caries. In Germany alone, it is estimated that 33 million people are affected. In infancy, H. pylori even affects 75% of the world's population. Infection with this bacterium need not, but can, contribute to a wide variety of symptoms, most of which directly affect the digestive tract - for example, chronic heartburn, reflux, frequent belching, gastritis and stomach pain, as well as loss of appetite or a permanent feeling of fullness.

 

The pathogen was first discovered in the early 1980s, but this went largely unnoticed at the time and initially had no direct consequences. However, years later, in 2005, the two scientists Barry Marshall and John Robin Warren were awarded the Nobel Prize for Medicine for their groundbreaking discovery - at that time, thanks to further research, the scientific community had long since recognized that H. pylori was at least partly responsible for many stomach diseases - such as a certain form of gastritis (inflammation of the gastric mucosa), namely type B gastritis, and the majority of all stomach ulcers. Interestingly, it has not yet been clarified how exactly transmission or infection with the pathogen occurs.

Combi Flora Antipylori with Lactobacillus reuteri

Antipylori with Lactobacillus reuteri serves for the direct treatment of an infection with the stomach bacterium Helicobacter pylori. The pathogen is considered to be the most common cause of gastric ulcers and also causes a number of symptoms that can often take on agonizing proportions. Thus, an infection with H. pylori can lead to gastrointestinal complaints such as frequent heartburn, excessive and constant feeling of fullness, acid reflux, loss of appetite and similar. Combi Flora Antipylori binds Helicobacter pylori and supports its elimination.

 

The specific bacterium contained in Combi Flora Antipylori by effective nature to bind the Helicobacter pylori pathogen is the patented Lacbacillus strain Pylopass™- Lactobacillus-reuteri DSM17648, which is present here in inactivated form, which gives it the unique ability to fight H. pylori by binding and excretion. Where H. pylori prefers to settle, in the stomach, the two bacteria combine - so you could say that one bacterium is "fought" with another bacterium. Pylopass™ was discovered during the evaluation of approximately 8000 different bacterial strains and was selected for its unique mechanisms of action in H pylori infections. Pylopass™ recognizes and docks with the surface receptors of Helicobacter pylori. This allows the bound bacteria to be excreted via the digestive tract. Important in this context: Combi Flora Antipylori from effective nature has no negative effects on the composition of the intestinal flora - the contained Pylopass™ strain binds exclusively to the Helicobacter pylori.

Antipylori recommended use

Take one capsule twice daily with a glass of water on an empty stomach (before meals) for one month.